- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Bio-Thera Solutions Gets Clearance to Start Phase 1 Trial of Ustekinumab Biosimilar
Bio-Thera Solutions, a global biotechnology company based in Guangzhou, China, said this week that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application to initiate a phase 1 clinical study to compare the pharmacokinetics and safety of BAT2206, a proposed ustekinumab biosimilar, to the reference Stelara in healthy volunteers.
Bio-Thera Solutions, a global biotechnology company based in Guangzhou, China, said this week that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application to initiate a phase 1 clinical study to compare the pharmacokinetics and safety of BAT2206, a proposed ustekinumab biosimilar, to the reference Stelara in healthy volunteers.
The clinical study will be a randomized, double-blind, parallel group, single-dose study that is expected to enroll approximately 270 people. The study will use US-sourced and EU-sourced reference products.
Bio-Thera joins other companies seeking to develop ustekinumab biosimilars, including Formycon (which is developing FYB202) and NeuClone.
“This IND approval represents an important milestone for our biosimilar pipeline,” said Shengfeng Li, chief executive office of Bio-Thera Solutions, in a statement. “BAT2206 will be the fifth biosimilar that Bio-Thera will advance into clinical development. It signifies Bio-Thera’s continued commitment to developing and commercializing biosimilar products for patients in China and around the world.”
In the United States, ustekinumab, a human interleukin-12 and -23 antagonist, is approved by the FDA to treat plaque psoriasis, psoriatic arthritis, Crohn disease, and ulcerative colitis.
Bio-Thera Solutions is developing several additional biosimilar products, including Qleti, a biosimilar to reference adalimumab (Humira) that was recently approved in China; it is also evaluating BAT1706, a bevacizumab biosimilar to Avastin, in a global phase 3 clinical trial.
Bio-Thera Solutions is also pursuing biosimilar versions of tocilizumab (Actemra), secukinumab (Cosentyx), and golimumab (Simponi).
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
